RNS Number : 9236B
ABCAM Plc
04 November 2009
For immediate release 4 November 2009
("Abcam" or "the Company")
Director and PDMR Dealings
Cambridge, UK: Abcam plc (AIM: ABC), the rapidly growing bioscience company that markets antibodies via its own online catalogue, announces the following transactions undertaken by employees of the Company:
On 3 November 2009, Jim Warwick, as Executive Director of the Company, exercised share options over 4,218 ordinary shares of 1 pence each in the Company at an exercise price of 224p per share. Following this transaction, Mr Warwick's total beneficial interest in the Company is 857,738 ordinary shares representing approximately 2.4 per cent. of the current issued share capital of the Company.
Also on 3 November 2009, Jane Cooke, a PDMR of the Company, exercised share options over 3,375 ordinary shares of 1 pence each in the Company at an exercise price of 224p per share. Following this transaction, Mrs Cooke's total beneficial interest in the Company is 3,724 ordinary shares representing approximately 0.01 per cent. of the current issued share capital of the Company.
For further information please contact:
Abcam + 44 (0) 1223 696000
Jonathan Milner, Chief Executive Officer
Jeffrey Iliffe, Chief Financial Officer
Numis Securities + 44 (0) 20 7260 1000
Michael Meade / Nick Westlake - Nominated Adviser
James Black - Corporate Broking
Buchanan Communications + 44 (0) 20 7466 5000
Mark Court / Mary-Jane Johnson / Stasa Filiplic
Notes for editors:
About Abcam plc
Abcam is a producer and distributor of research-grade antibodies headquartered in Cambridge, United Kingdom, with offices in Cambridge, Massachusetts, USA, Tokyo, Japan and Hong Kong. Abcam was admitted to AIM in November 2005 and trades under the ticker symbol ABC. The Company produces and distributes its own and third-party produced antibodies to academic and commercial users throughout the world. Product ordering is available through the Company's website www.abcam.com, where customers are also able to access up-to-date and detailed technical product data sheets. All the antibodies are sold under the Abcam brand name and the Company's vision is to build the world's largest online resource of high-quality and commercially viable antibodies. Abcam now has an online catalogue of over 56,000 products, most of which are antibodies, from over 250 suppliers and employs 243 staff in its four operating companies.
This information is provided by RNS
The company news service from the London Stock Exchange
END
RDSKZLBBKFBEFBE
